Combined pyrotinib and fulvestrant for hormone receptor-positive and HER2-positive metastatic breast cancer: A multicenter, single-arm, phase II trial.

Mutations in PIK3CA (response group, 2 of 10 [20%]; nonresponse group, 9 of 16 [56%]) and TP53 (response group, 7 of 10 [70%]; nonresponse group, 14 of 16 [88%]) were common and associated with increased unresponsiveness but did not reach statistical significance (Figure 4A ).

also in 111,027 other papers